Regents of the University of California’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Regents of the University of California’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,678	Closed	-$28.7K	–	29
2023 Q4	$28.7K	Hold	2,678	–	–	﹤0.01%	27
2023 Q3	$16.2K	Hold	2,678	–	–	﹤0.01%	28
2023 Q2	$18.5K	Hold	2,678	–	–	﹤0.01%	29
2023 Q1	$42K	Hold	2,678	–	–	0.01%	29
2022 Q4	$53.6K	Hold	2,678	–	–	0.01%	34
2022 Q3	$48K	Hold	2,678	–	–	0.01%	37
2022 Q2	$59K	Buy	+2,678	New	+$59.7K	0.01%	34

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regents of the University of California's ONCT Position: Q1 2024 in Review

Regents of the University of California sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 2,678 shares — an estimated $28.7K sold.

Regents of the University of California first reported a position in ONCT in Q2 2022 and held it in 7 quarters. The position peaked at $59K in Q2 2022. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

Regents of the University of California reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Regents of the University of California sold 2,678 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $28.7K.
Regents of the University of California first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
Regents of the University of California's Oncternal Therapeutics, Inc. Common Stock position peaked at $59K in Q2 2022.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Regents of the University of California's 13F filing for Q1 2024, filed 6 May 2024.